March 1, 2010Expert Review of Molecular Diagnostics
Multiple cytokine biomarkers in heart failure
Why the study?
Does multiplex cytokine biomarker analysis improve risk stratification and subclassification in patients with heart failure?
Population
Patients with chronic heart failure
Comparison
Multiplex cytokine biomarker analysis vs Single-assay measurement of cytokines
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports expanded heart failure research applications; leaves open clinical implementation pending bioinformatic advances.
Structured PICO
Does multiplex cytokine biomarker analysis improve risk stratification and subclassification in patients with heart failure?
P
Population
Patients with chronic heart failure
I
Intervention
Multiplex cytokine biomarker analysis (e.g., Luminex technology)
C
Comparator
Single-assay measurement of cytokines
O
Outcome
Risk stratification and subclassification for tailored therapysurrogate
Multiplex cytokine analysis holds promise for personalized heart failure therapy, but requires further biological understanding and bioinformatic tools before clinical implementation.
Limitations
- Current knowledge of the underlying biology of cytokine release in heart disease is limited
- A bioinformatic tool for interpretation of cytokine profiles is needed
Cite This Study
Vistnes et al. (2010) studied this question.